Oncolytic adenoviruses and immunopeptidomics: a convenient marriage

Our plain-English summary of Oncolytic adenoviruses and immunopeptidomics: a convenient marriage, by M. Garcia-Moure, A.G. Gillard, M.M. Alonso, et al (Molecular Oncology, 2024).

The study

• Authors: M. Garcia-Moure, A.G. Gillard, M.M. Alonso, J. Fueyo, C. Gomez-Manzano
• Journal: Molecular Oncology
• Published: 2024;18(4):781-784
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Oncolytic viruses (OVs) are biological therapeutic agents that selectively destroy cancer cells while sparing normal healthy cells. Besides direct oncolysis, OV infection induces a proinflammatory shift in the tumor microenvironment and the release of tumor-associated antigens (TAAs) that might induce an anti-tumor immunity. Due to their immunostimulatory effect, OVs have been explored for cancer vaccination against specific TAAs. However, this approach usually requires genetic modification of the virus and the production of a new viral vector for each target, which is difficult to implement for low prevalent antigens. In a recent study, Chiaro et al. presented an elegant proof of concept on how to implement the PeptiCRAd vaccination platform to overcome this limitation for the treatment of mesothelioma. Authors showed the feasibility of identifying immunogenic TAAs in human mesothelioma and using them to coat oncolytic adenovirus particles. The result was a customized virus-based cancer vaccine that circumvents time and resource-consuming steps incurred from genetically engineering viruses. Although some questions remain to be addressed, this interesting approach suggests novel strategies for personalized cancer medicine using oncolytic virotherapy.

© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

In plain English

This article was a commentary, not original research. The authors, writing in Molecular Oncology, discussed a recently published study by Chiaro et al. that combined immunopeptidomics with oncolytic virotherapy for mesothelioma using the PeptiCRAd platform, in which an oncolytic adenovirus particle is coated with tumour-specific peptides by electrostatic interaction rather than genetically engineered to express each antigen. The commentary described how, in that study, a chimeric oncolytic adenovirus Ad5/3 expressing OX40L and CD40L was coated with peptides selected from the MHC-I immunopeptidome of mesothelioma models and patient samples, with candidates filtered by predicted MHC-I affinity and immunogenicity and tested in PBMCs. The commentary noted that in that screen more than 80% of the eluted peptides were haplotype-specific and more than 60% were found in healthy tissues. The commentary authors concluded that PeptiCRAd is a platform for personalised virus-based cancer vaccination and that the Chiaro et al. work represents a further step towards clinical use of oncolytic virotherapy, while raising unresolved questions.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: commentary (editorial discussion of another group's published study)
• Who was studied: No population of its own; the commentary describes a study by Chiaro et al. that used mouse and human cell lines, human tissue specimens, mesothelioma models and patient samples
• Exposure: Not an exposure study; the intervention discussed was an oncolytic chimeric adenovirus Ad5/3 expressing OX40L and CD40L, coated with tumour-specific MHC-I peptides (PeptiCRAd)
• Main results:
  • As reported by the commentary about the Chiaro et al. immunopeptidome screen in mesothelioma models and patient samples: more than 80% of eluted peptides were haplotype-specific and more than 60% were found in healthy tissues
  • The commentary stated that the commented study showed a generic adenovirus particle can be loaded with any given peptide by electrostatic interaction, so one batch of virus can carry personalised targets
• The authors' conclusion: The commentary authors concluded that the Chiaro et al. manuscript is a further step towards clinical implementation of oncolytic virotherapy, and that PeptiCRAd is a platform for personalised virus-based cancer vaccination
• Limitations the authors state:
  • The commentary authors noted that human adenovirus replication is limited in murine cells, which they called a substantial limitation that may affect preclinical results
  • The commentary authors noted that peptide coating does not persist after the initial infection, so PeptiCRAd works as a first-shot strategy
  • The commentary authors noted that candidate selection did not account for factors such as patient haplotype, tumour specificity, driver role or clonality of the antigen

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Tumor Microenvironment, Mesothelioma.

Related studies

• An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression — T.T.T. Nguyen, M. Shingyoji, et al. (2021)
• Measles to the Rescue: A Review of Oncolytic Measles Virus — S. Aref, K. Bailey, et al. (2016)
• Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model — L. Kuryk, A.W. Møller, et al. (2018)
• Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus — T. Delaunay, C. Achard, et al. (2020)
• Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response — C. Achard, N. Boisgerault, et al. (2015)
• Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy? — T. Peikert (2020)

Browse more research in Molecular Oncology, or return to medical research.